CN114869899A - Pulsatillae saponin composition and application thereof in preparation of anti-aging food or medicine - Google Patents
Pulsatillae saponin composition and application thereof in preparation of anti-aging food or medicine Download PDFInfo
- Publication number
- CN114869899A CN114869899A CN202210325311.XA CN202210325311A CN114869899A CN 114869899 A CN114869899 A CN 114869899A CN 202210325311 A CN202210325311 A CN 202210325311A CN 114869899 A CN114869899 A CN 114869899A
- Authority
- CN
- China
- Prior art keywords
- saponin
- pulsatilla
- food
- aging
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007949 saponins Chemical class 0.000 title claims abstract description 37
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 31
- 229930182490 saponin Natural products 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 235000013305 food Nutrition 0.000 title claims abstract description 14
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 12
- 239000009806 pulsatillae Substances 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title claims description 3
- 241000123887 Pulsatilla chinensis Species 0.000 claims abstract description 20
- 229930184121 pulsatilla saponin Natural products 0.000 claims abstract description 17
- OUHBKBTZUPLIIA-OTEDBJMHSA-N [(2s,3r,4s,5s,6r)-6-[[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (1r,3as,5ar,5br,7ar,8r,9s,11ar,11br,13ar,13br)-9-[(2s,3r,4s,5s)-4,5-dihydroxy- Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](OC(=O)[C@@]34[C@H]([C@@H](CC3)C(C)=C)[C@@H]3[C@@]([C@]5(C)CC[C@H]6[C@](C)(CO)[C@@H](O[C@H]7[C@@H]([C@@H](O)[C@@H](O)CO7)O[C@H]7[C@@H]([C@H](O)[C@@H](O)[C@H](C)O7)O)CC[C@]6(C)[C@H]5CC3)(C)CC4)O2)O)[C@H](O)[C@H]1O OUHBKBTZUPLIIA-OTEDBJMHSA-N 0.000 claims abstract description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 239000002250 absorbent Substances 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 230000032683 aging Effects 0.000 abstract description 15
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 abstract description 14
- 239000000284 extract Substances 0.000 abstract description 5
- 230000007246 mechanism Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 239000007929 subcutaneous injection Substances 0.000 abstract description 4
- 238000010254 subcutaneous injection Methods 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 21
- 108010017842 Telomerase Proteins 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- 210000005013 brain tissue Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 210000001541 thymus gland Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- JLUQTCXCAFSSLD-NXEZZACHSA-N Anemonin Chemical compound C1=CC(=O)O[C@]11[C@@]2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-NXEZZACHSA-N 0.000 description 3
- JLUQTCXCAFSSLD-UHFFFAOYSA-N Anemonin Natural products C1=CC(=O)OC11C2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-UHFFFAOYSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000550 effect on aging Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 150000002966 pentacyclic triterpenoids Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pulsatilla chinensis saponin composition which comprises pulsatilla chinensis saponin B4 and pulsatilla chinensis saponin B5 in a weight ratio of 1-81: 9. The invention also discloses a food or a medicine containing the pulsatilla saponin composition and application thereof. The invention prepares a mouse aging model by using D-galactose (D-gal) subcutaneous injection, discusses the anti-aging effect and possible mechanism of the pulsatilla saponin B4+ B5 extract, and provides theoretical basis and experimental basis for the subsequent prevention and treatment of aging and related diseases by pulsatilla saponin.
Description
Technical Field
The invention relates to the technical field of medicines. More specifically, the invention relates to a pulsatilla saponin composition and application thereof in preparing anti-aging food or medicine.
Background
With the development of society, the proportion of the aged population increases year by year, and various age-related diseases are gradually called as problems troubling people. The method has the advantages of delaying the aging of population, reducing the disease incidence rate related to aging and becoming a research hotspot in various fields. Anti-aging is mainly embodied in lipid peroxidation, free radical scavenging, endocrine function regulation, immune function regulation and the like. Pulsatillae saponin B4 is pentacyclic triterpenoid saponin extracted from Pulsatilla chinensis (Thunb.) nakai of perennial herb of Ranunculaceae, and has antiinflammatory, antibacterial, immunoregulatory, antitumor, antioxidant and antiviral effects. However, the anti-aging effect of pulsatilla saponin is not clear.
Disclosure of Invention
The invention provides a pulsatilla chinensis saponin composition and application thereof in preparing anti-aging food or medicine, wherein a mouse aging model is prepared by subcutaneous injection of D-galactose (D-gal), the anti-aging effect and possible mechanism of pulsatilla chinensis saponin B4+ B5 extracts are discussed, and theoretical basis and experimental basis are provided for the subsequent prevention and treatment of aging and related diseases by pulsatilla chinensis saponin.
To achieve these objects and other advantages in accordance with the present invention, there is provided a pulsatillae radix saponin composition comprising pulsatillae radix saponin B4 and pulsatillae radix saponin B5 in a weight ratio of 1-81: 9.
Preferably, the food comprises the anemonin composition, food additives and food allowed by the food, and the purity of the anemonin B4 and the anemonin B5 is not less than 50%.
Preferably, the medicine contains the pulsatilla chinensis saponin composition and a pharmaceutically acceptable carrier, and the purity of pulsatilla chinensis saponin B4 and pulsatilla chinensis saponin B5 is not less than 50%.
Preferably, the medicament contains a therapeutically effective amount of hydrochloride, perchlorate, methanesulfonate, phosphate, citrate or sulfate of pulsatilla saponin and a pharmaceutically acceptable carrier.
Preferably, the pharmaceutically acceptable carrier includes diluents, solubilizers, cosolvents, disintegrants, dispersants, lubricants, flavoring agents, antioxidants, binders, absorbents, wetting agents, buffering agents, and crosslinking agents.
Preferably, the medicament is formulated into a pharmaceutically acceptable dosage form.
Preferably, the dosage form comprises pills, tablets, powders, capsules, granules, powders, dripping pills, drops, sprays, injections, suspensions, ointments, gels and suppositories.
The application of the pulsatilla saponin composition in preparing anti-aging food or medicine is provided.
Preferably, the dosage of the pulsatilla saponin is not less than 5 mg/kg-d.
The invention at least comprises the following beneficial effects:
the invention utilizes D-galactose (D-gal) to prepare a mouse aging model by subcutaneous injection, discusses the anti-aging effect and possible mechanism of the pulsatilla saponin B4+ B5 extract, the pulsatilla saponin B4+ B5 extract has the protection effect on aging, and the action mechanism of the pulsatilla saponin B4+ B5 extract can improve the learning and memory ability of mice aged by D-galactose, enhance the immunologic function, improve the activity of antioxidant in serum of the mice and enhance the activity of telomerase in brain tissues so as to play a role in delaying aging.
Additional advantages, objects, and features of the invention will be set forth in part in the description which follows and in part will become apparent to those having ordinary skill in the art upon examination of the following or may be learned from practice of the invention.
Drawings
FIG. 1 is a graph of the effect of B4+ HSC of the present invention on memory acquisition in aged mice;
FIG. 2 is a graph of the effect of B4+ HSC of the present invention on spleen and thymus indices in aging mice;
FIG. 3 is a graph of the effect of B4+ HSC of the present invention on T-SOD, GSH-Px, CAT activity and MDA levels in serum of aging mice;
FIG. 4 is a graph showing the effect of B4+ HSC of the present invention on SA- β -gal and telomerase activity in brain tissue of senescent mice.
Detailed Description
The present invention is further described in detail below with reference to the attached drawings so that those skilled in the art can implement the invention by referring to the description text.
It will be understood that terms such as "having," "including," and "comprising," as used herein, do not preclude the presence or addition of one or more other elements or combinations thereof.
It is to be noted that the experimental methods described in the following embodiments are all conventional methods unless otherwise specified, and the reagents and materials are commercially available unless otherwise specified.
1 test Material
1.1 test animals
SPF-grade healthy male C57 mice, 25-30g in weight and 2 months old, are purchased from Beijing Wintonlihua laboratory animal technology Co., Ltd, all laboratory animals are raised in a controllable environment at the room temperature of 18-24 ℃ and the humidity of 40-50%, the animals eat and drink water freely during the experiment period, and the circadian rhythm is normal.
1.2 major drugs and reagents
Pulsatillae saponin B4+ B5 (extracted in laboratory, B4+ B5 medicine purity is not less than 50%); d-galactose (Sigma Co.); vitamin E (Sigma corporation); paraformaldehyde (Chinese medicine analytically pure); 0.9% sodium chloride injection (Sichuan Kelun pharmaceutical Co., Ltd.); T-SOD, GSH-Px, CAT, MDA, SA-beta-gal and telomerase activity ELISA kit (enzyme immunoassay, Biotechnology, Inc.).
Pulsatillae saponin B4
Pulsatillae saponin B5
1.3 Main instrumentation
1/1000 precision balance (Metler-Torledo instruments Shanghai Co., Ltd., model: ME 204E); low temperature high speed centrifuge (Eppendorf Co., model 5425R); high-speed low-temperature tissue grinder (Wuhan Saiweier Biotech Co., Ltd., type: KZ-III-F)
2 animal modeling and administration
60 healthy male C57 mice (2 months of age, weight 25-30g) were randomly divided into blank control group (briefly described as blank group in the figure), model control group (briefly described as model group in the figure), positive drug control group (vitamin E100 mg/kg) (briefly described as VE 100mg/kg in the figure), pulsatilla saponin group (B4+ HSC 5, 10, 20mg/kg) (briefly described as B4+ HSC 5mg/kg, B4+ HSC 10mg/kg 10, B4+ HSC 20mg/kg in the figure), and 10 mice in each group. Model control group, positive drug control group, and radix Pulsatillae saponin group, and subcutaneous injection D-gal (200mg/kg) is administered for 42 days 1 time per day. The positive drug control group and the pulsatilla saponin group are administered by intraperitoneal injection from the 14 th day of molding for 28 days and 1 time per day. The blank control group and the model control group are injected with normal saline with the same quantity in the abdominal cavity.
3 detection index
(1) Effect of B4+ HSC on mouse memory acquisition (Morris water maze experiment): and (3) carrying out a water maze experiment with a period of 5 days, putting the mouse into the water pool from a random position for a positioning navigation experiment in the first 4 days, if the mouse finds the platform within 1min, enabling the mouse to stay on the platform for 5s, and if the mouse cannot find the platform independently, guiding the mouse to find the platform by an experimenter and enabling the mouse to stay on the platform for 20 s. Each mouse was trained twice daily. And the 5 th day is a space exploration experiment, the platform is removed, the mouse is put down from the position farthest away from the platform, the behavior of the mouse is observed and analyzed through ANY-maze, the ratio of the staying time of the mouse at the position of the platform to the total time is calculated and recorded as T1/T2, and the ratio is used for detecting the learning and memory acquiring capacity of the mouse to the water maze.
(2) Influence of B4+ HSC on thymus index and spleen index of mice
Weighing the thymus and the spleen of the mouse, and calculating the organ index of the mouse: organ index is organ mass (mg)/mouse body weight (g).
(3) Effect of B4+ HSC on T-SOD, GSH-Px, CAT Activity and MDA levels in serum
The mouse is subjected to eyeball blood sampling, and T-SOD, GSH-Px, CAT activity and MDA level in serum are detected according to the operation of the kit.
(4) Effect of B4+ HSC on SA- β -gal and telomerase Activity in mouse brain tissue
Mouse brain tissue is prepared into 10% brain tissue homogenate, and the levels of SA-beta-gal and telomerase (telomerase) in the mouse brain tissue homogenate are detected by an ELISA kit.
4 results of the experiment
4.1 Effect of B4+ HSC on memory acquisition Capacity in aging mice
The results of the Morris water maze test are shown in FIG. 1, compared with the blank control group, # P < 0.05; p < 0.05, P < 0.01, P < 0.001, compared to the model control group. Compared with a blank control group, the memory acquisition capacity of the mice in the model control group is weakened, and compared with the model control group, the positive drug control group and the pulsatilla saponin group (B4+ HSC 5, 10 and 20mg/kg) have certain improvement effects on the memory capacity of the mice.
4.2 Effect of B4+ HSC on spleen and thymus indices in aging mice
Taking spleen and thymus of the mice to calculate organ indexes, as shown in figure 2, and comparing with a blank control group, wherein # P is less than 0.001; p < 0.05, P < 0.01, P < 0.001, compared to the model control group. Compared with a blank control group, the spleen index and the thymus index of the mice in the model control group are reduced, and compared with the model control group, the spleen index and the thymus index of the mice in the positive drug control group and the pulsatilla saponin group (5, 10 and 20mg/kg) can be obviously increased. The pulsatilla chinensis saponin B4+ B5 is proved to play an anti-aging role by regulating immunity.
4.3 Effect of B4+ HSC on T-SOD, GSH-Px, CAT Activity and MDA levels in serum of aging mice
Using ELISA to detect T-SOD, GSH-Px, CAT activity and MDA level by taking mouse serum, as shown in figure 3, comparing with blank control group, # # # P < 0.001; p < 0.01, P < 0.001, compared to model control. Compared with a blank control group, the activities of T-SOD, GSH-Px and CAT in the serum of a mouse of the model control group are obviously reduced, and the MDA level is obviously increased. Compared with the model control group, the positive drug control group and the pulsatilla saponin group (5, 10 and 20mg/kg) can obviously increase T-SOD (figure 3A), GSH-Px (figure 3B) and CAT activity (figure 3C) in mouse serum and reduce MDA level (figure 3D). The pulsatilla chinensis saponin B4+ B5 is proved to possibly delay the aging through the antioxidation.
4.4 Effect of B4+ HSC on SA- β -gal and telomerase Activity in brain tissue of aging mice
Mouse brain homogenates were taken and assayed for SA-. beta. -gal and telomerase activity by ELISA, as shown in FIG. 4. Compared with a blank control group, the SA-beta-gal in the serum of the mouse of the model control group is obviously increased, and the activity of telomerase is obviously reduced. Compared with a model control group, the positive drug control group and the pulsatilla saponin group (5, 10 and 20mg/kg) can obviously reduce the SA-beta-gal level in the brain tissue of a mouse and increase the telomerase activity. The pulsatilla chinensis saponin B4+ B5 has the function of delaying senility.
5 conclusion
The experimental results show that the pulsatilla saponin B4+ B5 has the effect of delaying senescence, and the action mechanism of the pulsatilla saponin B4+ B5 can improve the learning and memory capacity of the mice aged by D-galactose, enhance the immune function, improve the activity of antioxidant enzyme in the serum of the mice and enhance the activity of telomerase in brain tissues so as to play a role in delaying senescence.
The number of apparatuses and the scale of the process described herein are intended to simplify the description of the present invention. Applications, modifications and variations of the present invention will be apparent to those skilled in the art.
While embodiments of the invention have been described above, it is not limited to the applications set forth in the description and the embodiments, which are fully applicable in various fields of endeavor to which the invention pertains, and further modifications may readily be made by those skilled in the art, it being understood that the invention is not limited to the details shown and described herein without departing from the general concept defined by the appended claims and their equivalents.
Claims (9)
1. The pulsatilla chinensis saponin composition is characterized by comprising pulsatilla chinensis saponin B4 and pulsatilla chinensis saponin B5 in a weight ratio of 1-81: 9.
2. The food comprising the pulsatilla saponin composition according to claim 1, wherein the food comprises the pulsatilla saponin composition and food additives and foods allowed to the food, and the purity of pulsatilla saponin B4 and pulsatilla saponin B5 is not less than 50%.
3. The medicine containing the pulsatilla chinensis saponin composition of claim 1, wherein the medicine contains the pulsatilla chinensis saponin composition and a pharmaceutically acceptable carrier, and the purity of pulsatilla chinensis saponin B4 and pulsatilla chinensis saponin B5 is not less than 50%.
4. The medicament of claim 3, which comprises a therapeutically effective amount of hydrochloride, perchlorate, methanesulfonate, phosphate, citrate or sulfate of pulsatillae saponin and a pharmaceutically acceptable carrier.
5. The pharmaceutical of claim 4, wherein the pharmaceutically acceptable carrier comprises diluents, solubilizers, cosolvents, disintegrants, dispersants, lubricants, flavoring agents, antioxidants, binders, absorbents, wetting agents, buffering agents, and crosslinking agents.
6. The medicament of claim 5, wherein the medicament is formulated into a pharmaceutically acceptable dosage form.
7. The medicament of claim 6, wherein the dosage form comprises pills, tablets, powders, capsules, granules, powders, drops, sprays, injections, suspensions, ointments, gels, suppositories.
8. Use of the pulsatilla saponin composition according to claim 1 in the preparation of an anti-aging food or medicament.
9. The use according to claim 8, wherein the pulsatillae radix saponin is administered in an amount of not less than 5 mg/kg-d.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210325311.XA CN114869899A (en) | 2022-03-30 | 2022-03-30 | Pulsatillae saponin composition and application thereof in preparation of anti-aging food or medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210325311.XA CN114869899A (en) | 2022-03-30 | 2022-03-30 | Pulsatillae saponin composition and application thereof in preparation of anti-aging food or medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114869899A true CN114869899A (en) | 2022-08-09 |
Family
ID=82668557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210325311.XA Pending CN114869899A (en) | 2022-03-30 | 2022-03-30 | Pulsatillae saponin composition and application thereof in preparation of anti-aging food or medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114869899A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110200981A (en) * | 2019-06-06 | 2019-09-06 | 中国药科大学 | The medical usage and its pharmaceutical composition of pentacyclic triterpene saponin |
| CN111110728A (en) * | 2020-02-14 | 2020-05-08 | 广西英路维特药物有限公司 | Pulsatilla chinensis extract and application thereof in preparation of medicines for preventing and/or treating cow mastitis |
-
2022
- 2022-03-30 CN CN202210325311.XA patent/CN114869899A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110200981A (en) * | 2019-06-06 | 2019-09-06 | 中国药科大学 | The medical usage and its pharmaceutical composition of pentacyclic triterpene saponin |
| CN111110728A (en) * | 2020-02-14 | 2020-05-08 | 广西英路维特药物有限公司 | Pulsatilla chinensis extract and application thereof in preparation of medicines for preventing and/or treating cow mastitis |
Non-Patent Citations (1)
| Title |
|---|
| 杨峰昆: "中药白头翁研究进展", 《中兽医医药杂志》, pages 23 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | Immunomodulatory activity of Panax ginseng extract | |
| US8829057B2 (en) | AMPK activating agent | |
| WO2018090983A9 (en) | Saponin compound for improving intestinal microflora, preparation method and use thereof | |
| US20220133763A1 (en) | Composition containing nicotinamide mononucleotide and mogroside, and application thereof | |
| CN114869899A (en) | Pulsatillae saponin composition and application thereof in preparation of anti-aging food or medicine | |
| CN102233009A (en) | Chinese medicinal composition for promoting nerve regeneration and preparation method and use thereof | |
| Miura et al. | Antidiabetic effect of nitobegiku in KK-Ay diabetic mice | |
| WO2015184990A1 (en) | Use of rutin in treatment of obesity and related diseases or delaying senescence | |
| Zhi‐qiang et al. | Effect of Qing Chang oral liquid on the treatment of artificially infected chicken coccidiosis and the cellular immunity | |
| Singh et al. | Enhancement of neuromuscular activity by natural specimens and cultured mycelia of Cordyceps sinensis in mice | |
| KR20220110443A (en) | Composition for preventing or treating of muscle disease or improvement of muscular functions comprising Rhododendron brachycarpum extract, Codonopsis Pilosulae Radix extract, or Sophora flavescens extract, or active component separated therefrom as an active ingredient | |
| Sinha et al. | Study of pattern of morbidity in children under 5 years and effect of Swarnaprashan on morbidity status | |
| CN111246849A (en) | Composition for enhancing learning and memory ability | |
| CN109620857A (en) | Peanut coat active component and its preparing the application in anti-fat antidiabetic medicine | |
| CN107929304A (en) | Application of the gentiamarin in non-alcohol fatty liver treatment | |
| CN110711198B (en) | Application of D-mannose in preparation of antidepressant | |
| WO2023195644A1 (en) | Composition for prevention, amelioration or treatment of asthma containing malus baccata var. mandshurica extract as active ingredient | |
| CN111467335B (en) | Pharmaceutical composition with synergistic blood sugar reducing effect and application thereof | |
| KR101717477B1 (en) | INTERFERON-GAMMA INHIBITOR, INTERLUKIN-4 INHIBITOR AND NF-kB INHIBITOR INCLUDING MUSKRAT(ONDATRA ZIBETHICUS) MUSK AND IMMUNOSUPPRESSIVE DRUG HAVING INTERFERON-GAMMA INHIBITION EFFECT, INTERLUKIN-4 INHIBITION EFFECT AND NF-kB INHIBITION EFFECT INCLUDING MUSKRAT(ONDATRA ZIBETHICUS) MUSK | |
| CN108096241A (en) | The medical usage of ginkgo lactone composition | |
| CN107462683B (en) | Research method for uric acid and blood sugar reducing effect of polygonum cuspidatum | |
| KR20070117889A (en) | A pharmaceutical composition comprising the extract of artemisa spp for treating or preventing inflammatory bowel disease | |
| CN114748519A (en) | Application of burdock leaf extract in preparation of product for improving Alzheimer's disease | |
| CN113476500A (en) | New use of stamen Nelumbinis and its extract in resisting fatigue | |
| ZAIDAN et al. | THE EFFECT OF SAUCE OF L. LEUCOCEPHALA SEEDS (LEUCAENA LEUCOCEPHALA [LAM.] DE WIT) ON LOWERING BLOOD GLUCOSE IN HYPERGLYCEMIC MICE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |